These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10675676)

  • 1. Prodrug to probe solution HFA pMDI formulation and pulmonary esterase activity.
    Seville PC; Simons C; Taylor G; Dickinson PA
    Int J Pharm; 2000 Feb; 195(1-2):13-6. PubMed ID: 10675676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
    Cheng YS; Fu CS; Yazzie D; Zhou Y
    J Aerosol Med; 2001; 14(2):255-66. PubMed ID: 11681657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants.
    Dickinson PA; Seville PC; McHale H; Perkins NC; Taylor G
    J Aerosol Med; 2000; 13(3):179-86. PubMed ID: 11066021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration.
    Shin HW; Barletta B; Yoonessi L; Meinardi S; Leu SY; Radom-Aizik S; Randhawa I; Nussbaum E; Blake DR; Cooper DM
    Clin Transl Sci; 2015 Oct; 8(5):445-50. PubMed ID: 26155923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical transition to non-CFC pressurized metered dose inhalers.
    Cripps A; Riebe M; Schulze M; Woodhouse R
    Respir Med; 2000 Jun; 94 Suppl B():S3-9. PubMed ID: 10919679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
    Salat D; Popov D; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S22-8. PubMed ID: 10919682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vivo lung delivery of hydrofluoroalkane-salbutamol formulation via metered-dose inhaler alone, with plastic spacer, or with cardboard tube.
    Fowler SJ; Wilson AM; Griffiths EA; Lipworth BJ
    Chest; 2001 Apr; 119(4):1018-20. PubMed ID: 11296163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
    Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The equivalent bronchodilator effects of salbutamol formulated in chlorofluorocarbon and hydrofluoroalkane-134a metered dose inhalers on the histamine-induced pulmonary response in dogs.
    Nogami-Itoh M; Yakuo I; Hammerbeck DM; Miller RL; Takeyama K
    Pharm Res; 1997 Feb; 14(2):208-12. PubMed ID: 9090711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler.
    Donnell D; Harrison LI; Ward S; Klinger NM; Ekholm BP; Cooper KM; Porietis I; McEwen J
    Eur J Clin Pharmacol; 1995; 48(6):473-7. PubMed ID: 8582466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro investigation of the effect of ambient humidity on regional delivered dose with solution and suspension MDIs.
    Shemirani FM; Hoe S; Lewis D; Church T; Vehring R; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2013 Aug; 26(4):215-22. PubMed ID: 23094687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salbutamol delivery from a hydrofluoroalkane pressurized metered-dose inhaler in pediatric ventilator circuits: an in vitro study.
    Wildhaber JH; Hayden MJ; Dore ND; Devadason SG; LeSouëf PN
    Chest; 1998 Jan; 113(1):186-91. PubMed ID: 9440589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system.
    Harrison LI; Cline A; Wells TM; Jacobson JP; Cooper KM; Chang SF; Nelson JR; Ekholm BP; Morganroth J
    Ther Drug Monit; 1996 Jun; 18(3):240-4. PubMed ID: 8738762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group.
    Baumgarten CR; Dorow P; Weber HH; Gebhardt R; Kettner J; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S17-21. PubMed ID: 10919681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The formulation of a pressurized metered dose inhaler containing theophylline for inhalation.
    Zhu B; Haghi M; Goud M; Young PM; Traini D
    Eur J Pharm Sci; 2015 Aug; 76():68-72. PubMed ID: 25956075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes.
    Wu L; Al-Haydari M; da Rocha SR
    Eur J Pharm Sci; 2008 Feb; 33(2):146-58. PubMed ID: 18083015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
    Ayres JG; Millar AB; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of a protein with propellant HFA 134a for aerosol delivery.
    Williams RO; Liu J
    Eur J Pharm Sci; 1999 Jan; 7(2):137-44. PubMed ID: 9845798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.